NO127470B - - Google Patents
Download PDFInfo
- Publication number
- NO127470B NO127470B NO03923/68A NO392368A NO127470B NO 127470 B NO127470 B NO 127470B NO 03923/68 A NO03923/68 A NO 03923/68A NO 392368 A NO392368 A NO 392368A NO 127470 B NO127470 B NO 127470B
- Authority
- NO
- Norway
- Prior art keywords
- solution
- blood
- hemoglobin
- phosphate buffer
- reducing agent
- Prior art date
Links
- 239000000243 solution Substances 0.000 claims description 67
- 210000004369 blood Anatomy 0.000 claims description 51
- 239000008280 blood Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 28
- 108010016797 Sickle Hemoglobin Proteins 0.000 claims description 25
- 239000003219 hemolytic agent Substances 0.000 claims description 15
- 239000008363 phosphate buffer Substances 0.000 claims description 15
- 239000003638 chemical reducing agent Substances 0.000 claims description 14
- 229930182490 saponin Natural products 0.000 claims description 14
- 150000007949 saponins Chemical class 0.000 claims description 14
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 6
- 206010018910 Haemolysis Diseases 0.000 claims description 4
- 230000008588 hemolysis Effects 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 239000011521 glass Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 208000007056 sickle cell anemia Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 5
- 241000997826 Melanocetus johnsonii Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010068308 Hemoglobin H Proteins 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- CCDRPBGPIXPGRW-JNKODXNQSA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CCDRPBGPIXPGRW-JNKODXNQSA-N 0.000 description 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108091005880 Hemoglobin F Proteins 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- PALNVYHUKHRDOP-UHFFFAOYSA-N UNPD162310 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O PALNVYHUKHRDOP-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007982 barbital buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67307167A | 1967-10-05 | 1967-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO127470B true NO127470B (en:Method) | 1973-06-25 |
Family
ID=24701215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO03923/68A NO127470B (en:Method) | 1967-10-05 | 1968-10-04 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3492095A (en:Method) |
| BE (1) | BE712385A (en:Method) |
| CH (1) | CH491386A (en:Method) |
| DE (1) | DE1773363A1 (en:Method) |
| ES (1) | ES352693A1 (en:Method) |
| FR (1) | FR1559272A (en:Method) |
| GB (1) | GB1213014A (en:Method) |
| IL (1) | IL28990A (en:Method) |
| NL (1) | NL6813544A (en:Method) |
| NO (1) | NO127470B (en:Method) |
| SE (1) | SE358029B (en:Method) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3847545A (en) * | 1972-05-18 | 1974-11-12 | Baxter Laboratories Inc | Diagnostic test for sickle-cell |
| US3877873A (en) * | 1972-06-26 | 1975-04-15 | Milton Winitz | Test for metabolic conditions in blood or serum |
| US3847482A (en) * | 1972-07-10 | 1974-11-12 | Bio Data Corp | Apparatus for detecting a change in turbidity of a solution |
| US3918905A (en) * | 1973-07-20 | 1975-11-11 | Biolog Corp Of America | Diagnostic test for the determination of sickling hemoglobinopathies |
| NO136062C (no) * | 1975-04-14 | 1977-07-13 | Henry Hirschberg | Fremgangsm}te og anordning for oppsamling av v{ske med innhold av radioaktive sporstoffer. |
| US4336157A (en) * | 1980-06-27 | 1982-06-22 | Baxter Travenol Laboratories, Inc. | Process for reclaiming biliverdin-containing fluids |
| US5064282A (en) * | 1989-09-26 | 1991-11-12 | Artel, Inc. | Photometric apparatus and method for measuring hemoglobin |
| US5236664A (en) * | 1991-04-08 | 1993-08-17 | University Of South Alabama | Apparatus for monitoring blood loss |
| US5231032A (en) * | 1991-04-08 | 1993-07-27 | University Of South Alabama | Method of monitoring blood loss |
| US5514592A (en) * | 1995-02-13 | 1996-05-07 | Medicus Technologies, Inc. | Method and composition for testing blood for hemoglobin S that incorporates mineral oil as an insoluble upper phase |
| US8003405B2 (en) * | 2005-12-16 | 2011-08-23 | Artel, Inc. | Calibrating dispensing device performance for complex and/or non-aqueous liquids |
| US7772008B2 (en) * | 2006-01-06 | 2010-08-10 | Artel, Inc. | Method and apparatus for determining liquid volume |
| US7998747B2 (en) * | 2006-09-15 | 2011-08-16 | Artel, Inc. | Quantitative dual-dye photometric method for determining dilution impact |
| US7791716B2 (en) * | 2008-04-07 | 2010-09-07 | Artel, Inc. | System and method for liquid delivery evaluation using solutions with multiple light absorbance spectral features |
| US8404158B2 (en) | 2008-04-07 | 2013-03-26 | Artel, Inc. | System and method for liquid delivery evaluation using solutions with multiple light absorbance spectral features |
| US8623659B2 (en) * | 2010-09-24 | 2014-01-07 | Saint Louis University | Sickle confirm modified hemoglobin solubility test |
| GB201415367D0 (en) * | 2014-08-29 | 2014-10-15 | Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K | Methods for detecting abnormalities in haemoglobin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2519997A (en) * | 1945-11-10 | 1950-08-22 | American Optical Corp | Comparison method for measuring the hemoglobin content of blood |
| US3000836A (en) * | 1958-09-02 | 1961-09-19 | Ginsburg Ben | Stabilized whole blood standard and method of making the same |
| GB1070745A (en) * | 1963-05-29 | 1967-06-01 | Noeller Hans Guenter | Apparatus for the determination of haemoglobin in blood |
| US3446751A (en) * | 1965-11-29 | 1969-05-27 | Brunswick Corp | Hemolyzing composition |
-
1967
- 1967-10-05 US US673071A patent/US3492095A/en not_active Expired - Lifetime
- 1967-11-16 GB GB52245/67A patent/GB1213014A/en not_active Expired
- 1967-11-21 IL IL28990A patent/IL28990A/xx unknown
-
1968
- 1968-03-07 FR FR1559272D patent/FR1559272A/fr not_active Expired
- 1968-03-12 CH CH361768A patent/CH491386A/fr not_active IP Right Cessation
- 1968-03-18 BE BE712385D patent/BE712385A/xx not_active IP Right Cessation
- 1968-03-21 SE SE03785/68A patent/SE358029B/xx unknown
- 1968-04-11 ES ES352693A patent/ES352693A1/es not_active Expired
- 1968-05-07 DE DE19681773363 patent/DE1773363A1/de active Pending
- 1968-09-23 NL NL6813544A patent/NL6813544A/xx unknown
- 1968-10-04 NO NO03923/68A patent/NO127470B/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB1213014A (en) | 1970-11-18 |
| CH491386A (fr) | 1970-05-31 |
| IL28990A (en) | 1971-07-28 |
| SE358029B (en:Method) | 1973-07-16 |
| FR1559272A (en:Method) | 1969-03-07 |
| BE712385A (en:Method) | 1968-07-31 |
| DE1773363A1 (de) | 1971-07-22 |
| NL6813544A (en:Method) | 1969-04-09 |
| ES352693A1 (es) | 1969-07-16 |
| US3492095A (en) | 1970-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO127470B (en:Method) | ||
| Mengher et al. | Non‐invasive tear film break‐uptime: sensitivity and specificity | |
| Larsson et al. | Posterior vitreous detachment: a combined clinical and physicochemical study | |
| Hong et al. | A simple method to measure drug effects on human sperm motility | |
| Barbezat, GO, Bowie, MD, Kaschula, ROC & Hansen | Studies on the small intestinal mucosa of children with protein-calorie malnutrition | |
| Agarwal et al. | Filtration of spermatozoa through L4 membrane: a new method | |
| Elekwa et al. | Effects of aqueous extracts of Zanthoxylum macrophylla roots on membrane stability of human erythrocytes of different genotypes | |
| Pappas | Structural and cytochemical studies of the cytoplasm in the family Amoebidae | |
| Segal et al. | Physiology, tion of N | |
| Camus et al. | A, B, O blood groups and clinical forms of schistosomiasis mansoni | |
| Irwin et al. | A Technic for Determining the Rate of Absorption of Fats: One Figure | |
| Duque et al. | Enteropathy in adult protein malnutrition: light microscopic findings | |
| de Oliveira Guerra et al. | Clinical and diagnostic aspects of American tegumentary leishmaniosis in soldiers simultaneously exposed to the infection in the Amazon Region | |
| Mandal et al. | Biochemical parameters of slowly liquefying human ejaculates | |
| Broadhurst et al. | Cytoplasmic inclusion bodies in the human throat | |
| JPH01158353A (ja) | 悪性高熱症の血液による診断法 | |
| Buchanan et al. | Fuel-mediated teratogenesis: symmetric growth retardation in the rat fetus at term after a circumscribed exposure to D-mannose during organogenesis | |
| Emiru | The cornea in kwashiorkor | |
| US4615877A (en) | Method of determining the oxidizing activity of a biological liquid, and a corresponding reagent | |
| Hardeman et al. | The Active serotonin uptake and the hypotonic shock response of human blood platelets | |
| Kagan | Studies on the clinical significance of the serum proteins: I. The protein content of normal human venous and capillary serum and factors affecting the accuracy of its determination | |
| Shiau et al. | Clinical and laboratory approaches to evaluate diarrheal disorders | |
| Sabhaya et al. | Pathology Laboratory | |
| Stewart | A Manual of Physiology: with practical exercises | |
| Rauf et al. | COMPARISON OF POTASSIUM ELECTROLYTE LEVELS IN BLOOD SPECI-MEN USING VACUUM TUBE CLOSE RED AND YELLOW AT TOTO KABILA HOSPITAL BONE BOLANGO DISTRICT |